Skip to content

Shikani versus FOB in awake nasal intubation of difficult airway high-risk adult patient in maxillofacial surgery: a randomized controlled trial

Shikani versus FOB in awake nasal intubation of difficult airway high-risk adult patient in maxillofacial surgery: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021515
Enrollment
Unknown
Registered
2019-02-25
Start date
2019-03-01
Completion date
Unknown
Last updated
2019-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

difficult airway

Interventions

FOB group:fibrobronchoscope
Shikani group:Shikani

Sponsors

Peking University School of Stomatology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) patients aged 18-60 years who scheduled to undergo elective Maxillofacial surgery and need to receive transnasal intubation; (2) 1difficult airway high-risk patients(assessed by responsible anesthesiologist)and arranged to receive awake intubation; (3) patients volunteered to join the study and signed the Informed consent.

Exclusion criteria

Exclusion criteria: (1) any contraindication to transnasal intubation; (2) revious history of schizophrenia, restlessness and other communication disorders; (3) patients with severe nasal diseases or have previous history of nasal/throat surgery; (4) patients with severe systemic diseases, ASA=III; (5) patients participated in other clinical trials in the last 3 months.

Design outcomes

Primary

MeasureTime frame
time of intubation;success rate of first intubation attempt;

Secondary

MeasureTime frame
vital signs of intubation;success rate of intubation;

Countries

China

Contacts

Public ContactTong Cheng

Peking University School of Stomatology

chengtong@foxmail.com+86 15811229030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026